To study the effects of Dexmedetomidine as an adjuvant in attenuating the haemodynamic stress response in patients undergoing laparoscopic surgery under general anesthesia

To determine the effect of Dexmedetomidine as an anaesthetic adjuvant in attenuating the haemodynamic stress response during pneumoperitoneum in patients undergoing laparoscopic surgery under general anaesthesia - Nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/055718

Enrollment

Registered

2023-07-26

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K802- Calculus of gallbladder without cholecystitis

Interventions

Intervention1: Dexmedetomidine: effect of Dexmedetomidine as an IV anaesthetic adjuvant in attenuating the haemodynamic stress response during pneumoperitoneum in patients with undergoing laparoscopic

Eligibility

Inclusion criteria

Inclusion criteria: 1. American Society of Anaesthesiologists Physical Status I and II patients. 2. Patients undergoing elective laparoscopic surgery under general anaesthesia, lasting upto 2 hours . 3. Both male and female patients in the age group 18â??60 years.

Exclusion criteria

Exclusion criteria: 1. Patient refusal or unwillingness to participate in the study. 2. ASA>=III 3. Patients allergic to dexmedetomidine. 4. Those who have coexisting cardio-respiratory disease e.g. ventricular dysfunction. 5. Patients with AV Block. 6. Patients on chronic beta blocker and opioid therapy. 7. Metabolic disease, endocrine disease, renal disease 8. Patients with morbid obesity i.e., BMI>=30 Kg/m2. 9. Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
To study the effect of dexmedetomidine as an anaesthetic adjuvant in attenuating they haemodynamic stress response during pneumoperitoneum in laparoscopic surgeries under general anaesthesia.Timepoint: at 4 weeks, 8 weeks, 24 weeks, 48 weeks and at the end of the trial	—

Secondary

Measure	Time frame
To demonstrate the effect of dexmedetomidine on requirement of isoflurane (MAC sparing effect) with the use of entropy as a measure of depth of anaesthesia.Timepoint: at 4 weeks, 8 weeks, 24 weeks, 48 weeks & at the end of the trial	—

Countries

India

Contacts

Public ContactDr Kiran Sharma

Indira Gandhi Medical College

kiran0213sharma.ks@gmail.com9459643654

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026